<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368953</url>
  </required_header>
  <id_info>
    <org_study_id>Lipsia-Yukon-DM</org_study_id>
    <nct_id>NCT00368953</nct_id>
  </id_info>
  <brief_title>YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus</brief_title>
  <official_title>A Prospective, Randomized, Multicenter Comparison of the Drug-Eluting Stent Systems YUKON Choice and TAXUS Liberté in Patients With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translumina GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <brief_summary>
    <textblock>
      Revascularisation procedures such as percutaneous coronary intervention are associated with
      overall worse outcomes in patients with diabetes mellitus. Implantation of coronary stents is
      associated with higher restenosis rates compared to non-diabetic individuals.

      There is only limited data available on the efficacy and safety of the novel Yukon Choice
      drug-eluting stent system specifically in patients with diabetes mellitus. The trial will
      determine the efficacy and safety of the novel Yukon Choice stent system compared to the well
      established Taxus Liberté stent system. The primary endpoint will be &quot;in-stent late lumen
      loss&quot; at 9 months as determined by invasive angiography.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;In-stent late lumen loss&quot; at follow-up-angiography (9 months)</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularisation rate</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularisation rate</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late loss (in-segment)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MLD und diameter of stenosis (%)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate index procedure (residual diameter stenosis &lt; 30%)</measure>
    <time_frame>0 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined MACE (cardiac death, myocardial infarction, emergency bypass, stent thrombosis, target lesion revascularization)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Yukon Choice stent system</intervention_name>
    <description>coronary stent implantation</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taxus Liberté stent system</intervention_name>
    <description>coronary stent implantation</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  diabetes mellitus

          -  symptoms (stable or unstable angina pectoris) or objective evidence of myocardial
             ischemia

          -  one or more de novo lesions in 1, 2 or 3 native coronary arteries

          -  clinically significant diameter of stenosis (50-99 % according to visual assessment of
             operator)

          -  lesion must be covered by stent length of no more than 24 mm and stent diameter of no
             more than 3,5 mm

          -  vessel diameter of no more than 4 mm in vessel area adjacent to stenosis

          -  informed consent

        Exclusion Criteria:

          -  unprotected left main disease

          -  complete occlusion of target vessel

          -  in-stent-restenosis

          -  stenoses of bypass grafts

          -  indication for bypass surgery

          -  bifurcation lesions (side branch &gt; 2,0 mm)

          -  thrombus in target lesion as visualized by angiography

          -  allergy or contraindication to concomitant medication (clopidogrel, aspirin, heparin,
             contrast media)

          -  acute myocardial infarction within preceding 48h

          -  participation in another trial

          -  pregnancy

          -  severe disorder of coagulation or platelet function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holger Thiele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heartcenter Leipzig GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Leipzig Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2006</study_first_submitted>
  <study_first_submitted_qc>August 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <last_update_submitted>February 1, 2010</last_update_submitted>
  <last_update_submitted_qc>February 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Holger Thiele</name_title>
    <organization>University of Leipzig</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

